Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
Chỉ hiển thị Multimedia

Use of RAS inhibitors associated with lower cancer risk in T2D
03 Oct 2022
bởiNatalia Reoutova
A real-world study of over 250,000 type 2 diabetes (T2D) patients from Hong Kong has found that use of renin-angiotensin-system inhibitors (RASIs) is independently associated with reduced risk of cancer, including diabetes-related cancers and cancer-specific mortality in diabetes.
03 Oct 2022

Adjuvant pembrolizumab continues to improve DFS in clear cell RCC
28 Sep 2022
bởiRoshini Claire Anthony
In patients with clear cell renal cell carcinoma (RCC), adjuvant pembrolizumab continues to improve disease-free survival (DFS) over placebo, according to extended follow-up of the phase III KEYNOTE-564 trial.
28 Sep 2022

First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
27 Sep 2022
Among older patients with metastatic breast cancer, first-line treatment with reduced-dose eribulin mesylate is reasonably safe but yields a low disease control rate, reports a recent phase II trial.
27 Sep 2022





